Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia

Sequential, non-randomised, single-blind Phase II trial enrolling four dose cohorts (10, 20, 40, 80 mg) to evaluate safety and effects of RL-007 on brain electrical activity and cognition in patients with schizophrenia.

Participants are admitted as in-patients for 5 days/4 nights; within each cohort participants receive sequences of active and matching placebo capsules (TID); assessments include EEG/ERP and cognitive testing on study days 2 and 4.